Evoke Reports Positive Results from Phase 2b Study of Metoclopramide Nasal Spray for Gastroparesis in Diabetics

by Charles Gross, Benzinga Editor
January 22, 2014 8:37 AM | 14 seconds read |
Evoke Pharma EVOK today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide. See full press release
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsGuidanceContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!